SANTA CLARA--- OptiMedica Appoints Mark A. Murray to Chief Financial Officer

Global ophthalmic company OptiMedica Corp. has named Mark A. Murray its chief financial officer, a newly created position. Murray brings to OptiMedica more than twenty-five years of senior financial experience in the medical device sector, with a wealth of knowledge and expertise in financial planning, accounting controls and compliance, operations, and mergers and acquisitions.

“Mark is an exceptional addition to our senior management team,” said Mark J. Forchette, president and chief executive officer of OptiMedica. “His experience, track record and strategic approach make him the ideal candidate to fill this critical role, and we look forward to working with him to meet the many growth goals we have set for the company.”

Prior to joining OptiMedica, Murray spent more than twenty years at Guidant Corporation and its predecessor, Advanced Cardiovascular Systems. While at Guidant, he held numerous officer-level financial positions; most recently, he served as vice president of finance for the company’s Vascular Intervention, Endovascular Solutions and Cardiac Surgery business units. Murray was also previously chief financial officer and vice president of finance and administration for Emphasys Medical Inc., an emerging interventional pulmonology company.

“There are several things that attracted me to OptiMedica, including the caliber of the company’s management team, its unique technology and the speed at which the company has executed to date,” said Murray. “With its current technology and deep pipeline, I believe OptiMedica is well poised to become a major player in ophthalmology, delivering significant benefits to patients, physicians, payers, employees and investors.”

About OptiMedica

Based in Santa Clara, Calif., OptiMedica Corp. is a global ophthalmic company dedicated to advancing the practice of ophthalmology for the benefit of physicians and their patients. The company holds the exclusive license to the PASCAL Photocoagulator technology, which was originally developed at Stanford University. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com.